TrialAnnals of the rheumatic diseases2005

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.

J van Holten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.